Physician

Balesh Sharma, MD

According to 2025 Medicare claims, Balesh Sharma, MD (NPI: 1578505483) practices medical oncology in the Brownsville-Harlingen, TX market, with the plurality of this provider's patient population coming from Cameron, TX. This provider's primary affiliated billing organization is TEXAS ONCOLOGY PA (NPI: 1811944101; TIN: 752131429) and primary practice location at 78521-1561.

Sharma's data goes back to 2015 and runs through 2024. For example, in 2024, this provider had 407 traditional Medicare patients, billed 72,189 HCPCS/CPT codes, and received $1,135,690 in Medicare payments. The top billing code was 99214 (Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more). Part D data shows 2,622 prescription claims across 448 beneficiaries totaling $6,340,867 in drug costs, led by Revlimid (Lenalidomide). DME data shows 12 claims. Open Payments data shows 61 records totaling $1,552. You can download detailed data with all billing codes (2015-2024). For more recent data, please contact us.

Over the past 10 years, this provider's Medicare Part B carrier billing has moved from a higher plateau to a lower plateau, from $2,323,510 to $1,135,690. In contrast, Part D prescription costs have moved from a lower plateau to a higher plateau, from $1,456,191 to $6,340,867. For DME billing, this provider has fewer than 5 years of reported data, so a reliable trend cannot be assigned.

Part B Carrier Billing Trend

Medicare payment trend, with N of patients and claim lines in the table.

Year	Patients	Clm Lines	Payment
2015	915	248,914	$2,323,510
2016	882	291,539	$2,532,310
2017	928	210,511	$2,429,725
2018	909	180,741	$2,149,176
2019	810	172,778	$2,482,034
2020	616	137,805	$1,580,066
2021	589	117,821	$1,522,881
2022	522	70,299	$1,081,126
2023	447	77,032	$1,186,421
2024	407	72,189	$1,135,690

Part D Events Trend

Drug cost trend, with N of patients and prescription claims in the table.

Year	Patients	Claims	Drug Cost
2015	463	2,637	$1,456,191
2016	427	2,447	$1,736,854
2017	460	2,659	$2,177,999
2018	464	2,845	$3,377,946
2019	473	3,128	$6,347,444
2020	501	3,073	$6,025,929
2021	419	2,711	$4,746,563
2022	416	2,531	$4,615,745
2023	410	2,176	$4,348,359
2024	448	2,622	$6,340,867

DME Billing Trend

Medicare payment trend, with N of patients and DME claim records in the table.

Year	Patients	Claims	Payment
2015	95	357	$78,666
2016	46	317	$62,109
2017	63	207	$29,769
2018	51	175	$18,507
2019	45	148	$14,908
2020	17	51	$3,743
2021	18	33	$2,718
2022	14	48	$2,666
2023	N/R	18	$1,411
2024	N/R	12	$775

* / # = suppressed by CMS; 0 = reported zero; N/R = not reported or blank.

Top 5 Part B carrier billing codes in 2024

By total payments.

Code	Description	Patients	Clm Lines	Total Payment
99214	Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more	301	811	$88
G2211	Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's	210	570	$12
80053	Blood test, comprehensive group of blood chemicals	304	707	$10
36415	Insertion of needle into vein for collection of blood sample	271	758	$9
85025	Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count	311	958	$8

Top 5 Part D drugs in 2024

By total drug costs.

Drug	Generic	Claims	Total Day Supply	Total Drug Cost
Revlimid	Lenalidomide	72	1,925	$1,048,628
Lenvima	Lenvatinib Mesylate	40	1,200	$939,490
Nubeqa	Darolutamide	40	1,200	$524,160
Verzenio	Abemaciclib	29	812	$435,351
Lynparza	Olaparib	24	720	$365,116

Top 5 DME services in 2024

By Total Medicare Payment Amount.

HCPCS Code	HCPCS Description	Supplier Rental Indicator	Total Supplier Beneficiaries	Total Supplier Claims	Total Medicare Payment Amount
L8000	Breast prosthesis, mastectomy bra, without integrated breast prosthesis form, any size, any type	N	N/R	12	$775

Open Payments Summary in 2024

Category	Definition	Records	Total Reported Amount	Top Related Entity
General Payments	Reported payment or transfer-of-value amount.	61	$1,552	AstraZeneca Pharmaceuticals LP
Research Payments	Reported research-related payment or transfer-of-value amount.	0	$0	N/R
Ownership / Investment Interests	Reported value of ownership or investment interests.	0	$0	N/R

Explore More Providers

FAQ

What Medicare data is available for Balesh Sharma, MD?

Tedicare shows public-source Medicare data for Balesh Sharma, MD (NPI 1578505483), including provider identity, specialty, market context, Medicare Part B activity, Part D prescribing, DME records, Open Payments where available, billing organization details, and ACO affiliation signals where available. Profile data covers 2015-2024, with current attribution based on 2025 claims where available.

Does Balesh Sharma, MD have ACO affiliation data?

No ACO affiliation record is shown in the available Tedicare data for this profile.

What billing organization is linked to Balesh Sharma, MD?

Balesh Sharma, MD is linked to TEXAS ONCOLOGY PA (billing NPI 1811944101) in the available physician profile data.

Does Balesh Sharma, MD have Open Payments data?

Balesh Sharma, MD has 61 connected Open Payments records in the available 2024 summary data.

Can I download physician-level Medicare data from Tedicare?

Yes. Tedicare provides sample physician export data and paid custom physician data exports for research, planning, outreach, and market analysis. Exports can include physician profile fields, market and specialty context, billing organization details, ACO affiliation signals where available, and Medicare utilization data.